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Objective: our aim was to evaluate whether somatic mutations in five genes were 
associated with an early age at presentation of breast cancer (BC) or serous ovar-
ian cancer (SOC). 
Methods: COSMIC database was searched for the five most frequent somatic 
mutations in BC and SOC. A systematic review of PubMed was performed. Young 
age for BC and SOC patients was set at ≤35 and ≤40 years, respectively. Age groups 
were also classified in <30years and every 10 years thereafter. 
Results: twenty six (1,980 patients, 111 younger) and 16 studies (598, 41 young-
er), were analyzed for BC and SOC, respectively. In BC, PIK3CA wild type tumor 
was associated with early onset, not confirmed in binary regression with estro-
gen receptor (ER) status. In HER2-negative tumors, there was increased frequen-
cy of PIK3CA somatic mutation in older age groups; in ER-positive tumors, there 
was a trend towards an increased frequency of PIK3CA somatic mutation in old-
er age groups. TP53 somatic mutation was described in 20% of tumors from both 
younger and older patients; PTEN, CDH1 and GATA3 somatic mutation was in-
vestigated only in 16 patients and PTEN mutation was detected in one of them. 
In SOC, TP53 somatic mutation was rather common, detected in more than 50% 
of tumors, however, more frequently in older patients. 
Conclusion: frequency of somatic mutations in specific genes was not associ-
ated with early-onset breast cancer. Although very common in patients with se-
rous ovarian cancer diagnosed at all ages, TP53 mutation was more frequently 
detected in older women.
Keywords: breast neoplasms, ovarian neoplasms, young adult, mutation. 
introduction
The probability of being diagnosed with an invasive can-
cer increases with age. In breast cancer, the incidence goes 
from 1.9%, in women below 50 years, to 2.3, 3.5 and 6.7% 
in women categorized within the age groups of 50 to 59, 
60 to 69 and 70 and over, respectively.1 Age-specific inci-
dence rates for epithelial ovarian cancer (per 100,000 
women) also increase with advancing age, varying from 
12.51 to 41.96 and 54.95 in the age groups of 40-44, 60-
64 and 75-79 years old.2 One reason for the increased in-
cidence rate of cancer at older ages is that carcinogenesis 
is a continuous process associated with the accumulation 
of genetic and epigenetic damage to the DNA, that takes 
place along a lifetime.3
Although breast cancer is the first leading cause of 
cancer death in females aged 20 to 59, in adolescents and 
younger adults, aged 15-39 years, there is still a paucity 
of information, concerning cancer incidence and behav-
ior. In this age group, breast cancer is the most common 
type of cancer, responsible for 14% of the cases.1,4 Young-
er age has been associated with a less favorable progno-
sis, which might be in part due to a lower proportion of 
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luminal A and higher proportion of triple negative and 
high grade tumors.5 However, molecular studies have also 
suggested that breast cancer in young patients may be 
characterized by unique disease biology, as compared to 
older patients, beyond subtype distribution.6
One of the predisposing factors for breast cancer is 
germline mutation in tumor suppressor genes such as 
BRCA1/2. In younger patients its frequency may be as 
high as 10.9 to 23%, as reported in women from different 
countries.7-12
Another cancer associated with BRCA1/2 germline 
mutation is epithelial ovarian cancer, where prevalence 
of the mutation in unselected patients is higher than in 
breast cancer, varying from 8-13%.13 In this cancer, high 
prevalence (24%) was described in women diagnosed in 
their forties with a lower prevalence in younger women 
in their thirties (11%).14 Epithelial ovarian cancer is not 
common in women below 40 years, and young age has 
been reported as a favorable prognostic factor. In analo-
gy with older ovarian cancer patients, serous ovarian can-
cer is the most frequent histology in young women ≤ 40 
years, but in contrast, low tumor grade is more common 
in this age group.15
However, BRCA1/2 germline mutation does not ex-
plain breast or epithelial ovarian cancer development in 
the majority of cases. A large number of cancer somatic 
alterations were recently characterized, most of which de-
posited in the COSMIC database (Catalogue of Somatic 
Mutation in Cancer – http://www.sanger.ac.uk/genetics/
CGP/cosmic/).16 Nevertheless, it is still not clear wheth-
er there might be any association between gene somatic 
mutations and age of diagnosis. Hence, we performed a 
systematic review and meta-analysis to evaluate a possi-
ble association between somatic alterations in specific 
genes in breast and serous ovarian cancer samples and 
age at cancer diagnosis.
Methods
Study eligibility and identification
At first, the COSMIC database was searched for the iden-
tification of five of the genes most frequently mutated 
(somatic mutations) in breast cancer, namely PIK3CA 
(25%), TP53 (23%), CDH1 (11%), GATA3 (7%) and PTEN 
(5%). Search strategy was: breast tissue, subtissue (all), 
cancer histology, subhistology (all). Date References 
shown in COSMIC for these selected genes were reviewed. 
The search was performed on October 2013.
A literature search through PubMed database fol-
lowed, to ensure that studies including somatic altera-
tions in these specific genes in breast cancer were not 
missed. PubMed was searched for using the key words 
specified: breast neoplasms [MeSH terms] AND “somat-
ic” [all fields] AND (“2003/10/13” [PDat]: “2015/02/11” 
[PDat] AND “humans” [MeSH terms]) and (breast neo-
plasm [MeSH terms]) AND “somatic”) AND “PIK3CA”; 
followed by TP53; P53; CDH1; GATA3 and PTEN. After 
consulting COSMIC and PubMed, a total of 821 unique 
articles were identified. After exclusions, which were main-
ly due to lack of individual data for age or gene mutation, 
26 studies were selected (Table 1).
The same strategy used above was employed to ana-
lyze ovarian cancer, including identification of the five 
most frequently mutated genes in COSMIC, as of Octo-
ber 2013, which were TP53 (65%), KRAS (6%), BRCA1 (4%), 
NF1 (4%) and CHEK2 (3%). Search strategy in COSMIC 
was: ovary tissue, subtissue (all), cancer histology and se-
rous cancer subhistology. Only serous cancer was includ-
ed due to its higher frequency and differential frequen-
cies of somatic gene mutations detected in different 
histologies. Subsequently, PubMed was searched for us-
ing the key words specified: ovarian neoplasms [MeSH 
terms] AND somatic [all fields] AND (“2003/10/18” 
[PDat]: “2015/02/11” [PDat] AND “humans” [MeSH 
terms]) and ovarian cancer (MesH terms) AND somatic 
AND TP53, followed by: P53; KRAS, BRCA1, NF1, CHK2 
and CHEK2. Among 439 unique articles, after exclusions 
mainly due to absence of individual data for age and mu-
tation, sixteen studies were selected (Table 1).
Selection and exclusion criteria for studies
The following inclusion criteria were used for selection 
of the publications: (a) studies in which data was avail-
able for each individual patient, concerning age and so-
matic mutation; (b) studies employing whole tumor ge-
nome or exome sequencing; (c) studies evaluating mutations 
in the five candidate genes in tumor specimens using di-
rect sequencing. Exclusion criteria were: (a) studies with-
out individual data; (b) mutation analyzed only through 
loss of heterozigosity (LOH), Restriction fragment length 
polymorfism (RFLP), single-strand conformation poly-
morphism (SSCP) not confirmed by direct sequencing; 
and (c) other techniques not related with direct sequenc-
ing.
References from selected studies, reviews and meta-
analysis were checked for other relevant publications. Au-
thors of manuscripts were contacted by email for missing 
information, most authors replied, but only one was able 
to report on missing clinical data.27 Almost all abstracts 
from studies published in other languages than English 
were reviewed, but neither one met the inclusion criteria.
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TABLE 1 Studies selected in breast and serous ovarian cancer analysis.
Author Patients (n) Gene Methodology
Breast cancer
Ding et al.17 1 All WGS and/or exome sequencing
Yost et al.18 2 All WGS and/or exome sequencing
Nik-Zainal et al.19 21 All WGS and/or exome sequencing
Banerji et al.20 103 All WGS and/or exome sequencing
Shah et al.21 63 All WGS and/or exome sequencing
Stephens et al.22 100 All WGS and/or exome sequencing
Ellis et al.23 317 All WGS and/or exome sequencing (77 patients), PIK3CA, TP53, CDHI and GATA3 
(240 patients)
Jiao et al.24 15 All WGS and/or exome sequencing
Craig et al.25 14 All WGS and/or exome sequencing
Benvenuti et al.26 85 PIK3CA Direct sequencing
Miron et al.27 80 PIK3CA Direct sequencing
Martins et al.28 75 PIK3CA Direct sequencing
Hernandez et al.29 13 PIK3CA Sequenom MassArray – direct sequencing
Lima et al.30 1 PTEN Direct sequencing
Jong et al.31 89 TP53 DHPLC – direct sequencing
Lavarino et al.32 31 TP53 SSCP – direct sequencing
Wistuba et al.33 2 TP53 SSCP – direct sequencing
Masri et al.34 19 TP53 Direct sequencing
Lien et al.35 14 TP53 Direct sequencing
Eachkoti et al.36 25 TP53 SSCP – direct sequencing
Vincent-Salomon et al.37 48 TP53 Direct sequencing
Aceto et al.38 4 TP53 SSCP – direct sequencing
Curtis et al.39 820 TP53 Direct sequencing
Ripamonti et al.40 1 TP53 Direct sequencing
Sjoblom et al.41 36 TP53/GATA3/CDHI Direct sequencing
Ang et al.42 1 TP53/PIK3CA Sequenom MassArray – direct sequencing
Serous ovarian cancer
Bell et al.43 309 All WGS and/or exome sequencing
Jones et al.44 17 All WGS and/or exome sequencing (8 patients) and direct sequencing (KRAS – 9 patients)
Zhang et al.45 1 All WGS and/or exome sequencing
Bashashati et al.46 5 All WGS and/or exome sequencing
Merajver et al.47 15 BRCAl SSCP – direct sequencing
Koul et al.48 2 BRCAl PTT – SPSS – direct sequencing
Enomoto et al.49 10 KRAS Direct sequencing
Fu et al.50 10 KRAS Direct sequencing
Mandai et al.51 21 KRAS SSCP – direct sequencing
Otsuka et al.52 14 TP53 SSCP – direct sequencing
Kringen et al.53 24 TP53 TTGE – direct sequencing
Dehari et al.54 6 TP53/KRAS Direct sequencing
Birch et al.55 10 TP53/KRAS Direct sequencing
Wojnaeowicz et al.56 95 TP53/KRAS Direct sequencing
Sangha et al.57 41 TP53/KRAS/NF1 PTT – direct sequencing
Kinde et al.58 18 TP53/KRAS/NF1 Direct sequencing
WGS: whole genome sequencing; DHPLC: denaturing high pressure liquid chromatography; SSCP: single-strand conformation polymorphism.
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Data collection
The aim of the present study was to evaluate the rate of 
somatic mutations in five specific genes, disregarding the 
type of mutation and the number of mutations in each 
gene in the same sample. In case of multiple reports of 
the same data, only one was taken into consideration. 
Each abstract was reviewed by two investigators indepen-
dently. In case of any disagreement, the issue was dis-
cussed with the group until a consensus was reached.
A Microsoft Excel Database was assembled with in-
cluded trials and reasons for exclusion of excluded trials. 
A second datasheet was assembled with the included arti-
cles reporting each patient and mutation found: identifi-
cation of patient, age, tumor histology; histological grade, 
stage and mutation (presence or absent). Additionally, for 
breast cancer patients, information about node, ER, PR 
and HER2, as reported by the authors, was included.
Data analysis
In this work, cut off ages for early age breast cancer and 
ovarian cancer were 35 and 40 years, respectively. Group 
ages were then stratified in 7 groups: (1) <30 years, (2) 30-
39 years, (3) 40-49 years, (4) 50-59 years, (5) 60-69 years, 
(6) 70-79 years and (7) ≥80 years. Age groups with less 
than 10 patients were not taken into consideration for 
analysis.
Chi-square or Fisher’s exact tests were used to evalu-
ate association between variables. Odds ratio (OR) and 
95% confidence intervals (95% CIs) were estimated using 
logistic regression. Correlation between variables was eval-
uated through Pearson correlation and correlation coef-
ficients (r) are provided. P values ≤ 0.05 were considered 
significant. The analysis was performed using Statistical 
Package for the Social Sciences 18.0 (SPSS).
results
A total of 1980 patients, 5.6% of whom aged less than 36 
years, were included in the 26 studies selected (Table 1). In 
these studies, data available comprehended each patient’s 
age and specific mutations. At first, breast cancer patients 
were separated in two subsets: younger (≤35 years) vs. old-
er (>35 years). Most patients, both younger and older, were 
diagnosed with invasive ductal cancer (84% in both groups); 
however, high histological grade (73 vs. 46.6%; p<0.001) 
and ER-negative tumor (45.5 vs. 30.6%; p=0.006) as well as 
node positivity (63.6 vs. 45.8%; p=0.044) and advanced dis-
ease, clinical stage III/IV (28.8 vs. 14.9%; p=0.003), were 
mainly detected in younger patients.
PIK3CA somatic mutation was more frequently detect-
ed in tumors from older patients as compared with young-
er patients (26.7 vs. 6.7%; p=0.014). TP53 somatic mutation 
was described in similar frequencies of younger and older 
patients, 21.6 and 20.1%, respectively. 
PTEN, CDH1 and GATA3 somatic mutation was inves-
tigated only in a small number of younger patients (16 pa-
tients each). PTEN somatic mutation was detected in 3.3% 
of all patients and in 1/16 younger patients. GATA3 and 
CDH1 somatic mutations were analyzed in 672 and 564 
patients, respectively, and detected in approximately 8% of 
them, none aged ≤35 years. CDH1 somatic mutation was 
detected in almost half (47%) of the lobular cancers and 
median age of patients was higher in patients harboring 
CDH1 somatic mutation than in patients not harboring 
the mutation (62 vs. 57 years; p=0.007, Mann Whitney test).
Each variable significantly associated with age (his-
tological grade, node, clinical stage, estrogen receptor 
[ER] status) was then tested concomitantly with PIK3CA 
somatic mutation in the subsets of younger and older 
breast cancer patients, using binary logistic regression. 
This analysis showed a trend towards a lower chance of 
ER-positive tumor in younger, as compared with older 
patients (OR: 0.433; 95% CI: 0.181-1.036; p=0.060); but 
not for PIK3CA somatic mutation (OR: 0.233; 95% CI: 
0.029-1.712; p= 0.149).
An association between gene mutations and tumor 
subtypes was already described; hence, the whole group of 
patients was then tested for these associations, indepen-
dent of age. PIK3CA somatic mutation was more frequent-
ly detected in ER-positive than in ER-negative tumors (28 
vs. 8%; p<0.001) and TP53 somatic mutation was more fre-
quently detected in ER-negative (42.8 vs. 10.1%; p<0.001) 
and HER2-positive tumors (27.5 vs. 18.6%; p=0.006). Con-
sidering the whole group of patients who had both PIK-
3CA and TP53 analyzed, only 5.5% (35/637) presented both 
PIK3CA and TP53 somatic mutations, while 49.6% (316/637) 
presented both PIK3CA wild-type (wt) and TP53 wt.
Following the hypothesis that the number of somat-
ic mutations accumulate along the lifetime,3 the next step 
was to evaluate PIK3CA and TP53 somatic mutations ac-
cording to age groups, classified as <30 years and then ev-
ery 10 years. Frequency of PIK3CA somatic mutation in-
creased in older age groups and reached about 30% in 
patients aged more than 60 years; TP53 somatic muta-
tion peaked in 20-30% in patients aged 30-59 years, de-
creasing thereafter (Figure 1).
ER and HER2 status was also determined according 
to age groups, as another aim was to evaluate presence of 
somatic mutations according to tumor characteristics 
(ER and HER2) in the age groups. Frequency of ER-pos-
itive tumors was directly correlated with age and reached 
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80% in women aged 60 years or more. In contrast, fre-
quency of HER2-positive tumors was indirectly correlat-
ed with age and maximum level, around 25%, was detect-
ed in patients aged less than 30 years (Figure 1).
Afterwards, frequency of PIK3CA and TP53 somatic 
mutation was evaluated in ER-positive/negative and 
HER2-positive/negative tumors, according to age groups. 
There was a trend towards an increased frequency of PIK-
3CA somatic mutation in ER-positive tumors, according 
to age groups (Figure 2). For patients aged less than 40 
years, frequency of PIK3CA somatic mutation in ER-pos-
itive tumors was low, near 10%. After this age, more than 
25% of the ER-positive tumors presented PIK3CA somat-
ic mutation. In HER2-negative tumors, a positive corre-
lation in frequency of PIK3CA somatic mutation accord-
ing to age groups was detected. No correlation was 
observed in frequency of TP53 mutation according to 
tumor characteristics and age (Figure 2).
Among 16 studies selected in serous ovarian cancer, 
598 samples were evaluated (with 6.8% aged less than 41 
years), while other histologies, comprehending 95 sam-
ples, were disregarded from further analysis (Table 1). Pa-
tients were grouped in younger (≤40 years) and older age 
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HER2pos (n=7, r=-0.859, p=0.013)
HER2neg (n=7, r=0.802, p=0.030)
FIGURE 1 Frequency of PIK3CA and TP53 somatic mutation and ER and HER2 expression (positive and negative) according to different age 
groups (Pearson correlation) (PIK3CA n=6, after exclusion of age group < 30 years, as less than 10 patients were available).
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disease (clinical stage III/IV). High grade tumors (histo-
logical grade III) were mainly observed in older patients 
(88.8 vs. 65%; p<0.001). TP53 somatic mutation was rath-
er common, detected in more than 50% of tumors in both 
age groups, however, more frequently in older patients 
(86.7 vs. 55.2%; p<0.001). KRAS somatic mutation was de-
scribed in less than 3% of the tumors; however, only 35 
younger patients were included, among whom, one with 
mutation. A low frequency of somatic mutation was also 
observed for BRCA1 (3.5%), NF1 (5.5%) and CHECK2 (0.3%), 
none detected in younger patients.
Frequency of TP53 mutation was also tested in age 
groups, classified as <30 years and then every 10 years, and 
detected in more than 75% of tumors from patients aged 40 
years or more. This evaluation was not performed for the 
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ERpos (n=6, r=0.802, p=0.055)
ERneg (n=5, r=0.572, p=0.313)
HER2pos (n=3, r=0.461, p=0.695)
HER2neg (n=6, r=0.861, p=0.028)
ERpos (n=7, r=-0.229, p=0.621)
ERneg (n=5, r=-0.539, p=0.348)
HER2pos (n=5, r=0.572, p=0.314)











































FIGURE 2 Frequency of PIK3CA and TP53 somatic mutation according to expression ER and HER2 (positive and negative) according to 
different age groups (Pearson correlation). Age groups with less than 10 patients were excluded.
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discussion
We have investigated whether frequency of somatic mu-
tations would differ in younger and older cancer patients. 
At first, frequency of somatic mutations in PIK3CA, TP53, 
CDH1, GATA3 and PTEN was evaluated in younger and 
older breast cancer patients, using a cut off of 35 years. 
PIK3CA somatic mutation was found less frequently in 
younger (≤ 35 years) than older patients (>35 years) (6.7 
vs. 26.7%, respectively). In addition, an association be-
tween PIK3CA somatic mutation and positive expression 
of ER was detected, as already reported.59-63 However, in 
binary logistic regression, only odds ratio (OR) for ER-
positive expression (but not for PIK3CA somatic muta-
tion) was lower in younger patients.
Analyzing some other manuscripts, that were not 
included in the present meta-analysis (since individu-
al age of cancer diagnosis was not available), no asso-
ciation between PIK3CA somatic mutation and age was 
found. In these studies, however, a cut point was set at 
a higher age, 50-55 years or menopause.62-64 On the oth-
er hand, a trend towards association between PIK3CA 
somatic mutation in older patients was also already re-
ported.65
PIK3CA somatic mutation frequency was, then, in-
vestigated in different age groups (<30 years and then ev-
ery 10 years) and a direct correlation was verified. Fur-
thermore, a direct correlation of frequency of PIK3CA 
somatic mutation in ER-positive tumors and age groups 
was detected, indicating that PIK3CA somatic mutation 
frequency increases in aging patients. Hence, it seems like-
ly PIK3CA somatic mutation rate increases in ER positive 
tumors in aging patients.
In the present analysis, TP53 somatic mutation fre-
quency was similar (around 20%) in both younger and 
older breast cancer patients. Considering frequency of 
TP53 somatic mutation in the age groups, it tended to in-
crease in the early age groups, reaching almost 30% in pa-
tients aged 40-49 years, going downwards in older age 
groups. In agreement, in another manuscript, which was 
not included in this meta-analysis due to unavailability 
of age for all patients, but only for TP53 somatic muta-
tion carriers, TP53 somatic mutation was reported to be 
17% in early onset breast cancer patients (< 37 years).66 In 
addition, a fall in TP53 somatic mutation rate in older 
age groups, above 59 years, was also reported in a large 
study.67 Discrepancies however, evaluating TP53 somatic 
mutation frequency and age were also shown, varying 
from no association68,69, to reduced70 or increased age71 
being associated with TP53 somatic mutation. In the pres-
ent series, TP53 somatic mutation was more frequent in 
ER-negative tumors (41.8%), in accordance with some au-
thors63,67 but in contrast with others, that found no asso-
ciation.69,71
In the current analysis, PTEN, CDH1 and GATA3 so-
matic mutation was investigated only in a small number 
of younger breast cancer patients (16 patients), in whom 
it seemed to be very infrequent, even absent as in the case 
of PTEN and CDH1. In contrast, it is interesting to ob-
serve that another recent work reported that GATA3 so-
matic mutations tended to occur in tumors from patients 
aged ≤ 40 years, mainly in luminal-like subtype.72 In the 
present analysis, median age of patients presenting CDH1 
somatic mutation was 62 years, in accordance with an-
other study, where mean age was 64.9 years, indicating 
that it is mainly detected in older patients.73
In serous ovarian cancer, TP53 somatic mutation was 
rather common and mutation frequency increased with 
advancing age, in agreement with previous studies.74-76 In 
addition, KRAS somatic mutation rate was low (<3%), also 
reflecting data from other authors.77 BRCA1 somatic mu-
tation was detected in tumors from 3.5% of the patients, 
and even though no mutations were detected in young-
er patients, only 16 were aged less than 41 years. A simi-
larly low BRCA1 somatic mutation rate was also detect-
ed in another study of epithelial ovarian cancer. In that 
analysis all affected patients presented familial history of 
breast and/or ovarian cancer and tumor subtype speci-
ficity was not reported.78
conclusion
In breast cancer samples, there is a trend towards increas-
ing PIK3CA somatic mutation rate in ER-positive tumors 
in aging patients. TP53 somatic mutation peaks around 
20-30% in patients aged 30-59 years, decreasing thereaf-
ter. In addition, CDH1 somatic mutation seems to be un-
likely in younger patients. In ovarian cancer samples TP53 
somatic mutation is rather frequent, detected in more 
than 50% of tumors in younger and more than 75% of tu-
mors in older patients.
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resuMo
Mutações somáticas em pacientes jovens com câncer de 
mama e epitelial de ovário: revisão e metanálise
Objetivo: avaliar se mutações somáticas em câncer de 
mama e seroso de ovário estão associados com pacientes 
jovens. 
Métodos: com base no COSMIC, foram selecionados os 
cinco genes mais frequentes mutados em câncer de mama 
e seroso de ovário. Em seguida, realizou-se uma revisão 
sistemática no PubMed. Pacientes jovens foram classifi-
cadas com ≤35 anos e ≤40 anos para câncer de mama e 
seroso de ovário, respectivamente. Classificaram-se tam-
bém as pacientes em grupos etários de ≤30 anos, separa-
dos a cada 10 anos. 
Resultados: vinte e seis (1.980 pacientes, 111 jovens) e 16 
estudos (598, 41 jovens) foram selecionados para câncer 
de mama e seroso de ovário, respectivamente. Em câncer 
de mama, pacientes jovens apresentaram baixa frequência 
de mutações somáticas em PIK3CA. Tumor HER2 negati-
vo foi associado a mutações somáticas em PIK3CA no gru-
po etário mais avançado, e em tumores ER positivos foi 
observada uma tendência a essa associação. Mutações so-
máticas em TP53 foram observadas em 20% dos tumores, 
em ambos os grupos (≤35 anos vs. ≥35 anos). Mutações so-
máticas em PTEN, CDH1 e GATA3 foram analisadas em 16 
pacientes e apenas uma apresentou mutação em PTEN. Em 
câncer seroso de ovário, mutações somáticas em TP53 fo-
ram detectadas em mais que 50% dos tumores; entretanto, 
foram mais frequentes em pacientes idosas. 
Conclusão: a frequência de mutações somáticas nos ge-
nes selecionados não foi associada com pacientes jovens. 
Embora muito comum em pacientes com câncer seroso 
de ovário, mutações somáticas em TP53 foram mais fre-
quentes em pacientes mais velhas.
Palavras-chave: neoplasias da mama, neoplasias ovaria-
nas, adulto jovem, mutação.
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